

Uppsala 2019-04-10

FarmPharma receives EU funding SME instrument Phase I

As previously announced, FarmPharma AB that is subsidiary to Double Bond Pharmaceutical Int. AB, has submitted an application to the European Commission for an SME instrument grant within the framework of the Horizon2020 program, where groundbreaking innovation projects with market-generating potential can be supported. The company funds alone to implement a more in-depth and up to date business plan for continued successful development of InterferOX. The project under the name InFarm has now been funded with the amount of SEK 500,000, which corresponds to the entire sought amount and is the ceiling for this type of grant. Moreover, an international business coach sponsored by EASME and Tillväxtverket is being allocated to the project.

"It's a big moment for us to receive our first support from the European Commission for the project and also get the most relevant business coach handpicked for us," - comments Iulia Karlsson, CEO of FarmPharma. - It is an important quality stamp for our business and we are committed do everything in our hands and beyond to continue delivering at a high level and at a high speed".

More about SMEi phase I: <https://ec.europa.eu/programmes/horizon2020/en/h2020-section/sme-instrument>

More about InterferOX: www.farmpharma.se

This information is information that Double Bond Pharmaceutical International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 10 of April 2019.

Full Company Name: Double Bond Pharmaceutical International AB (publ)

Corporate identity: 556991-6082

Stock short name: DBP B

Share ISIN code: SE0007185525

For more info, contact

Igor Lokot, CEO



Homepage: <http://www.doublebp.com/>

E-mail: info@doublebp.com

Blog: <http://blog.doublebp.com>

Follow us on LinkedIn (<https://www.linkedin.com/company/double-bond-pharmaceutical?trk=co-feed-likes-one>) and Twitter (<https://twitter.com/DoubleBondPharm>)!

Information on Double Bond Pharmaceutical International AB

DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company's own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.